by Allison Sit Healio covered three studies from the June issue of the Journal of Drugs in Dermatology, including one about dapsone gel for acne patients with skin of color.…
by Allison Sit Three studies from the May issue of the Journal of Drugs in Dermatology are already making news. Healio wrote about a skincare regimen that can address adverse…
by Allison Sit Dermatology Times, HAPPI, Healio and HealthDay all wrote about an April article in the Journal of Drugs in Dermatology that was one of one of the largest,…
by Allison Sit Dermatology Advisor, Dermatology Times and Healio all covered recent articles in the Journal of Drugs in Dermatology. One study, “Cysteamine Isobionic-Amide Complex Versus Kligman’s Formula for the…
by Allison Sit Dermatology Advisor, Dermatology News, Healio, Medriva and Medscape all covered a Journal of Drugs in Dermatology study about the long-term safety and effectiveness of topical clascoterone for…
by Allison Sit The Journal of Drugs in Dermatology made news in Healio recently with several articles including one about a combination therapy for non-melanoma skin cancer. The study, “Cryosurgery…
by Allison Sit Healio wrote about a recent Journal of Drugs in Dermatology study on telehealth usage from a physician’s perspective. The study, “Telemedicine Versus Teledermatology Usage and Perception Among…
by Allison Sit A Journal of Drugs in Dermatology study on the availability of oral minoxidil made news in several media outlets, including NBC News, HealthDay, Practical Dermatology and Dermatology…
Healio featured several September JDD studies in its recent dermatology news coverage including a study on using fractional lasers for skin cancer prevention. The study, “Fractional Laser for Prevention of…
Dermatology Times featured a JDD study on whether race plays a factor in access to biologics. The study, “No Racial Differences Found in Access to Biologics: A Population-Based Study of…
Healio featured a JDD study on the use of tildrakizumab for plaque psoriasis. Jayme Heim, MSN, FNP-BC, and colleagues wrote, “Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe…
Click Here to Watch Video Abstract Background: Patients with skin of color (SOC), defined as Fitzpatrick skin types IV to VI, and of varying ethnicities are under-represented in dermatology. This…
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our cookie policy | Continue
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.